4/10
07:47 pm
sldb
Buy Solid Biosciences: Unpacking Its Main Value Driver [Seeking Alpha]
Low
Report
Buy Solid Biosciences: Unpacking Its Main Value Driver [Seeking Alpha]
4/5
07:44 am
sldb
British billionaire fined $5M, sentenced to 3 years probation for insider trading [Yahoo! Finance]
Medium
Report
British billionaire fined $5M, sentenced to 3 years probation for insider trading [Yahoo! Finance]
4/4
04:53 pm
sldb
Joe Lewis: How one of Britain's richest people broke insider trading laws [Yahoo! Finance]
Low
Report
Joe Lewis: How one of Britain's richest people broke insider trading laws [Yahoo! Finance]
4/3
04:15 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
4/3
04:05 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
12:02 pm
sldb
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug [Yahoo! Finance]
Low
Report
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug [Yahoo! Finance]
4/2
04:58 am
sldb
87-year-old billionaire Joe Lewis will be punished enough with a less than 18-month sentence for insider trading, U.S. prosecutors say: ‘Punishment may come in many forms' [Fortune]
Medium
Report
87-year-old billionaire Joe Lewis will be punished enough with a less than 18-month sentence for insider trading, U.S. prosecutors say: ‘Punishment may come in many forms' [Fortune]
4/2
01:17 am
sldb
UK Billionaire Lewis Deserves Leniency for Insider Tips, US Says [Yahoo! Finance]
Medium
Report
UK Billionaire Lewis Deserves Leniency for Insider Tips, US Says [Yahoo! Finance]
4/2
12:38 am
sldb
UK Billionaire Lewis Deserves Leniency for Insider Tips, US Says [BNN Bloomberg (Canada)]
Medium
Report
UK Billionaire Lewis Deserves Leniency for Insider Tips, US Says [BNN Bloomberg (Canada)]
4/1
07:53 am
sldb
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 [Yahoo! Finance]
Medium
Report
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 [Yahoo! Finance]
4/1
07:45 am
sldb
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
High
Report
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
3/28
08:04 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its "outperform" rating re-affirmed by analysts at William Blair.
High
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its "outperform" rating re-affirmed by analysts at William Blair.
3/27
07:15 am
sldb
Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
Medium
Report
Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
3/27
07:00 am
sldb
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
Medium
Report
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
3/18
03:09 pm
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
3/18
02:53 pm
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at Barclays PLC from $8.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at Barclays PLC from $8.00 to $21.00. They now have an "overweight" rating on the stock.
3/15
08:08 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $16.00 price target on the stock.
Medium
Report
Solid Biosciences Inc. (NASDAQ: SLDB) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $16.00 price target on the stock.
3/14
08:30 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $8.00.
Medium
Report
Solid Biosciences Inc. (NASDAQ: SLDB) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $8.00.
3/13
01:55 pm
sldb
Catalyst announces US launch of Duchenne drug Agamree Mar. 13, 2024 1:46 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]
Low
Report
Catalyst announces US launch of Duchenne drug Agamree Mar. 13, 2024 1:46 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]
3/13
07:44 am
sldb
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Medium
Report
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
3/7
07:16 am
sldb
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD [Yahoo! Finance]
Low
Report
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD [Yahoo! Finance]
3/7
07:00 am
sldb
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
Medium
Report
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
3/6
08:00 am
sldb
Solid Biosciences to Participate at Upcoming Investor Conferences
Low
Report
Solid Biosciences to Participate at Upcoming Investor Conferences
1/30
10:11 am
sldb
Muscular Dystrophy Association Announces Recipient of 2024 MDA Legacy Award for Achievement in Research, is Jeffrey Chamberlain, Ph.D., Leading Professor in Gene Therapy [Yahoo! Finance]
Low
Report
Muscular Dystrophy Association Announces Recipient of 2024 MDA Legacy Award for Achievement in Research, is Jeffrey Chamberlain, Ph.D., Leading Professor in Gene Therapy [Yahoo! Finance]